Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Eir Ventures is a Nordic life sciences venture capital fund founded to finance the development of innovative medicine. The firm operates from offices in Stockholm, Sweden, and Copenhagen, Denmark, and manages a portfolio of eight companies. Their team includes experienced professionals with MD and PhD qualifications, enhancing their expertise in the life sciences sector.
Eir Ventures invests in high-potential life science opportunities, targeting pre-seed, seed, and Series A stages. Their strategy includes both early-stage projects and more mature companies, aiming to balance lower-risk investments with high-potential innovations in biotech and healthcare.
Notable companies in Eir Ventures' portfolio include Henlez, which focuses on enzyme-based treatments for skin conditions; Strike Pharma, developing immunotherapeutic vaccines for solid tumors; and GutCRINE, exploring bacterial strains in the gut microbiome for metabolic therapies. Other investments include ArgusEye, Moleculent, Purpose Pharma, Hoba Therapeutics, and Scenic Biotech.
Submit your pitch through their website's contact form at [URL]. Ensure your proposal highlights the transformative potential of your healthcare solution.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.